Company Filing History:
Years Active: 2021
Title: Aljaz Kajtna: Innovator in Pharmaceutical Processes
Introduction
Aljaz Kajtna is a notable inventor based in Ljubljana, Slovenia. He has made significant contributions to the field of pharmaceuticals, particularly in the conversion of ascomycin to pimecrolimus. His innovative approach has the potential to enhance industrial applications and reduce costs in the pharmaceutical industry.
Latest Patents
Kajtna holds a patent for a process to convert technical ascomycin into purified pimecrolimus. The patent describes an improved method where crude ascomycin is chlorinated with triphenylphosphine and N-chlorosuccinimide (NCS) to yield crude pimecrolimus. This crude product is then purified using high-pressure liquid chromatography (HPLC) followed by crystallization. The process allows for the removal of close homologs of pimecrolimus without the need for prior purification of the ascomycin starting material. This advancement may lead to more cost-effective and industrially viable methods for producing pimecrolimus.
Career Highlights
Aljaz Kajtna is currently employed at Meda Ab, where he continues to work on innovative pharmaceutical processes. His expertise in chemical processes and patent development has positioned him as a valuable asset in the industry.
Collaborations
Kajtna collaborates with talented professionals such as Borut Gabriel and Ajna Lukic. Their combined efforts contribute to the advancement of pharmaceutical innovations and the successful implementation of new processes.
Conclusion
Aljaz Kajtna's work in the conversion of ascomycin to pimecrolimus exemplifies the impact of innovation in the pharmaceutical industry. His contributions not only enhance the efficiency of drug production but also pave the way for more affordable healthcare solutions.